Trial for next generation IMiD CC-122 opens for myeloma patients

A Phase I clinical trial investigating the safety and efficacy of a new drug, known as CC-122, has recently opened for relapsed and refractory myeloma patients. Made by Celgene, CC-122 is regarded as a next generation immunomodulatory (IMiD) drug which works by targeting the protein cereblon in a similar manner to the existing IMiDs thalidomide,…

Details

Kyprolis® combination launched in the UK for relapsed myeloma patients

Amgen has announced it has made Kyprolis (carfilzomib) available in the UK following the recent licensing approval by the European Commission. Kyprolis can now be used in combination with Revlimid and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The company is expected to resubmit a technology appraisal…

Details